SG10202009266PA - Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid - Google Patents

Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Info

Publication number
SG10202009266PA
SG10202009266PA SG10202009266PA SG10202009266PA SG10202009266PA SG 10202009266P A SG10202009266P A SG 10202009266PA SG 10202009266P A SG10202009266P A SG 10202009266PA SG 10202009266P A SG10202009266P A SG 10202009266PA SG 10202009266P A SG10202009266P A SG 10202009266PA
Authority
SG
Singapore
Prior art keywords
chlorophenoxy
isoquinoline
cyano
carbonyl
hydroxy
Prior art date
Application number
SG10202009266PA
Inventor
Claudia Witschi
Michael D Thompson
Jung Min Park
Michael P Arend
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202009266P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of SG10202009266PA publication Critical patent/SG10202009266PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG10202009266PA 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid SG10202009266PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361756361P 2013-01-24 2013-01-24

Publications (1)

Publication Number Publication Date
SG10202009266PA true SG10202009266PA (en) 2020-10-29

Family

ID=50073508

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505748UA SG11201505748UA (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
SG10202009266PA SG10202009266PA (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201505748UA SG11201505748UA (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Country Status (16)

Country Link
US (1) US9643928B2 (en)
EP (1) EP2951159B1 (en)
JP (1) JP6437456B2 (en)
KR (1) KR102233081B1 (en)
CN (1) CN105452227B (en)
AU (1) AU2014209319B2 (en)
CA (1) CA2899024C (en)
DK (1) DK2951159T3 (en)
ES (1) ES2694297T3 (en)
HK (1) HK1217331A1 (en)
IL (1) IL240066B (en)
MX (1) MX360048B (en)
RU (1) RU2666144C2 (en)
SG (2) SG11201505748UA (en)
TW (1) TWI685487B (en)
WO (1) WO2014116849A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
EP2872488B1 (en) 2012-07-16 2018-08-22 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
HUE034409T2 (en) 2012-07-16 2018-02-28 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
EP3708154A1 (en) 2013-06-06 2020-09-16 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (en) 1978-04-27 1979-11-08 Hoechst Ag NEW ISOCHINOLINE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
DE3233424A1 (en) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt ISOCHINOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (en) 1993-05-17 1994-11-30 Ciba-Geigy Ag Use of inhibitors of HIV-protease for the treatment of tumorous diseases
ATE149485T1 (en) 1993-11-02 1997-03-15 Hoechst Ag SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDE ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
ES2101421T3 (en) 1993-11-02 1997-07-01 Hoechst Ag SUBSTITUTED HETERO-CYCLIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
AU7526798A (en) 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
FR2779963A1 (en) 1998-06-22 1999-12-24 Centre Nat Rech Scient New composition useful for treat cancer, comprises compound with affinity for mitochondrial benzodiazepine receptors and agent to induce apoptosis
IT1302677B1 (en) 1998-10-15 2000-09-29 Zambon Spa BENZAZINIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (en) 2000-02-09 2003-11-18 Rotta Research Lab DERIVATIVES OF THYROSIN WITH ANTI LEUKOTRIENIC ACTIVITY, PROCEDURES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE.
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (en) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Naphthalene derivatives which inhibit Comt enzymes
DE10110750A1 (en) 2001-03-07 2002-09-12 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
CN100522946C (en) 2001-12-06 2009-08-05 法布罗根股份有限公司 Stabilization of hypoxia inducible factor (HIF) alpha
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20060173046A1 (en) 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (en) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド Aryl and heteroaryl compounds, compositions and methods of use
JP2008507097A (en) 2004-07-15 2008-03-06 パワープリサイス・ソリューションズ・インコーポレーテッド One-time operating state detection method and apparatus
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN101849943A (en) 2005-06-06 2010-10-06 菲布罗根公司 Use the improved treatment for anemia of HIF alpha stabilizers
MX2007016160A (en) 2005-06-15 2008-03-07 Fibrogen Inc Use of hif 1alfa modulators for treatment of cancer.
EP2044028B1 (en) * 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
AU2007218051A1 (en) * 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
WO2007115315A2 (en) 2006-04-04 2007-10-11 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
WO2009075826A1 (en) * 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Also Published As

Publication number Publication date
US9643928B2 (en) 2017-05-09
AU2014209319B2 (en) 2018-04-19
ES2694297T3 (en) 2018-12-19
KR20150129679A (en) 2015-11-20
MX2015009617A (en) 2016-04-20
RU2666144C2 (en) 2018-09-06
DK2951159T3 (en) 2018-11-19
EP2951159B1 (en) 2018-08-22
EP2951159A1 (en) 2015-12-09
CA2899024A1 (en) 2014-07-31
CN105452227A (en) 2016-03-30
SG11201505748UA (en) 2015-08-28
AU2014209319A1 (en) 2015-08-27
JP2016505071A (en) 2016-02-18
JP6437456B2 (en) 2018-12-12
IL240066A0 (en) 2015-09-24
KR102233081B1 (en) 2021-03-29
HK1217331A1 (en) 2017-01-06
MX360048B (en) 2018-10-19
TWI685487B (en) 2020-02-21
IL240066B (en) 2019-08-29
CA2899024C (en) 2022-01-04
CN105452227B (en) 2018-05-29
US20160002170A1 (en) 2016-01-07
TW201444800A (en) 2014-12-01
WO2014116849A1 (en) 2014-07-31
RU2015134420A (en) 2017-03-03

Similar Documents

Publication Publication Date Title
IL245865B (en) Crystalline form i of ibrutinib
IL240066B (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
PL2742051T3 (en) Amorpous form of the dolutegravir sodium salt
AP2014007615A0 (en) Solid forms of nematocical sulfonamides
EP2970081A4 (en) Salts of treprostinil
GB2514233B (en) Press-granulating process of non-ductile salts
RU2016118399A3 (en) 4-aminomethylbenzoic acid derivative
EP3071554A4 (en) Crystalline forms of lesinurad and its sodium salt
PL3041945T3 (en) Production of galacto-oligosaccharides
IL244758B (en) Preparation of hydroxy-benzylbenzene derivatives
GB201111396D0 (en) Monitoring of livestock
RS58930B1 (en) Novel hydroxamic acid derivative or salt thereof
HK1220444A1 (en) Crystals of laquinimod sodium and improved process for the manufacture thereof
PL2970086T3 (en) Recovery of 3-hydroxypropionic acid
GB2519787B (en) Process for the preparation of herbicidal carboxylic acid salts
HK1212978A1 (en) Novel derivatives of sinapinic acid
GB201208293D0 (en) Hydrochlorice salt of peptide
EP3027739A4 (en) Modified cells for production of blood cells
EP2976326A4 (en) Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms
EP2782902A4 (en) Derivatives of phenoxyisobutyric acid
HK1214596A1 (en) Crystalline form of a substituted thiazolylacetic acid triethylamine salt
GB201322785D0 (en) Manufacture of lactic acid
AU2013903615A0 (en) Process for preparation of herbicidal salts
AU2013904433A0 (en) Process for preparation of herbicidal salt
PL3071575T3 (en) Preparation of normorphinans